UPDATE: MediChem Signs First Protein Structure Deal | GenomeWeb

This story has been updated from a previous version.

NEW YORK, April 11 - MediChem Life Sciences of Chicago said Wednesday it had signed its first protein structure deal with Celgene’s Signal Research Division, reflecting outside interest in MediChem’s drug discovery strategy, which combines its recently acquired X-ray crystallography and informatics capabilities along with its traditional medicinal chemistry approach.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: transcriptome patterns of Zika-infected cells, updated Comparative Toxicogenomics Database, and more.

BMJ study says that about half of former hematology-oncology regulators now work for industry.

Science should wish PhDs who leave academia well, a Nature editorial says.

New York-based doctors announce the birth of a baby boy whose parents underwent mitochondrial transfer therapy, New Scientist reports.